My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Evolus, Inc. - Common Stock (NQ:EOLS)

6.980 +0.240 (+3.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit

May 15, 2024

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2024

From Evolus

Via Business Wire

Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year

May 10, 2024

From Evolus, Inc.

Via Business Wire

Recap: Evolus Q4 Earnings ↗

March 07, 2024

Via Benzinga

Earnings Outlook For Evolus ↗

March 06, 2024

Via Benzinga

AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗

February 14, 2024

A Relative Strength Rating upgrade for AbbVie shows improving technical performance.

Via Investor's Business Daily

EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

EOLS stock results show that Evolus beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Evolus Reports First Quarter 2024 Results and Provides Business Update

May 07, 2024

From Evolus

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

May 02, 2024

Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday!

Via InvestorPlace

Evolus to Report First Quarter Financial Results on May 7, 2024

April 23, 2024

From Evolus

Via Business Wire

Evolus Inc. (NASDAQ: EOLS) Leading the Way in Wednesday Trading Based on Percentage Gain

January 17, 2024

Via Investor Brand Network

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

April 17, 2024

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 12, 2024

From Evolus

Via Business Wire

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 26, 2024

From Evolus

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 21, 2024

Via Benzinga

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

March 11, 2024

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 08, 2024

From Evolus

Via Business Wire

EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 ↗

March 07, 2024

EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

March 07, 2024

From Evolus

Via Business Wire

Evolus Announces Results from European Head-to-Head Filler Trial

March 01, 2024

From Evolus

Via Business Wire

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

February 27, 2024

From Evolus

Via Business Wire

Earnings Scheduled For March 7, 2024 ↗

March 07, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Via Benzinga

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

February 22, 2024

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 09, 2024

From Evolus

Via Business Wire

Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings ↗

February 01, 2024

Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level.

Via Investor's Business Daily

Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 29, 2024

Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped...

Via Benzinga

SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday ↗

January 29, 2024

U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported...

Via Benzinga

Topics Stocks

Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker ↗

January 17, 2024

Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 17, 2024

Via Benzinga

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

January 16, 2024

From Evolus

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.